Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Janssen Pharmaceuticals Inc.

Division of Johnson & Johnson
www.janssenpharmaceuticalsinc.com

Latest From Janssen Pharmaceuticals Inc.

Keeping Track: US FDA Okays BMS’ Zeposia In MS, Nixes Lilly/BI’s Empagliflozin For Type 1 Diabetes

The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.

US FDA Performance Tracker Approvals

Experts Say COVID-19 Battle Needs More Funding, Cooperation

Adequate funding and joined-up global cooperation are two top priorities needed to combat COVID-19, a panel of pharma executives told this year’s BIO-Europe Spring.

Coronavirus COVID-19 Clinical Trials

Opioid Trial, Other Pharma Cases Postponed In Wake Of COVID-19

Delays expected to have cascading effect beyond the current crisis; Federal Circuit to hear arguments remotely.

Legal Issues Coronavirus COVID-19

FDA And FTC Offer Advice On Biosimilar Barriers

Speakers suggest ways to eliminate barriers to biosimilar uptake, but Janssen pushes back, saying there is need to inform physicians and patients of a biosimilar's interchangeability status. Biosimilar advocates want prescriber incentives, labeling changes, and FDA education on interchangeability.

Biosimilars FDA
See All

Company Information

UsernamePublicRestriction

Register